Marinos C. Dalakas MDProfessor, Neurology, and Director, Neuromuscular Diseases, Thomas Jefferson University, Philadelphia, Pennsylvania; Chief, Neuroimmunology Unit, National and Kapodistrian University of Athens, Athens, Greece
Dr. Marinos Dalakas is Professor of Neurology and Director of the Neuromuscular Division at Thomas Jefferson University School of Medicine in Philadelphia. He is Professor of Neurology and Chief of the Neuroimmunology Laboratory in the Department of Pathophysiology at the University of Athens Medical School in Athens, where he has been Emeritus Professor since 2016. Dr. Dalakas is an appointed member in various scientific societies and is a member of the American Neurological Association, the American Academy of Neurology, the European Neurological Society, and the International Society of Greek Neuroscientists, among other professional organizations.
Dr. Dalakas has published widely. His areas of research are broad and include neuroimmunology, neurovirology, genetics, and immunotherapies in neurologic diseases. He has focused on neuropathies, myopathies, dystrophies, ALS, multiple sclerosis, and various autoimmune neurological disorders, with the application and design of new treatments.
He completed a 3-year fellowship training in neuromuscular diseases at the Medical Neurology Branch of the NINCDS in Bethesda, Maryland and an additional 5-year training in Neuroimmunology/Neurovirology at NINDS. He subsequently served as Chief of the Neuromuscular Diseases Section of the NINDS, NIH, a position he held for 20 years before joining Thomas Jefferson University.
DisclosuresMarinos C. Dalakas M.D. serves on the Scientific Advisory Board or has received speaking honoraria the last 2 years from: Baxter, Novartis, Hoffman La Roche, and Octapharma. He served as a consultant for Therapath. He has received honoraria from TAND (Therapeutic Advances in Neurological Disorders) for serving as Associate Editor. He has received institutional grant support to Thomas Jefferson Univerity or the University of Athens Medical School from CSL, Grifols, Dysimmune diseases Foundation, Genesis, Genzyme, Merck-Serono, and Novartis.
Recent Contributions to PracticeUpdate:
- 2020 Top Stories in Neurology: Rituximab Treatment for New-Onset Generalized Myasthenia Gravis: Promising Effects for Long-Term Remission
- Contactin-1 Autoimmunity
- Neurologic Syndromes Related to Anti-GAD65
- Safety and Efficacy of Intravenous Bimagrumab in Inclusion Body Myositis
- 2018 Top Stories in Neurology: Neuromuscular Diseases
- 2017 Top Stories in Neurology: New Therapeutics in Spinal Muscular Atrophy
- 2017 Top Stories in Neurology: Neuromuscular Complications of Checkpoint Inhibitors
- 2016 Top Stories in Neurology: Myasthenia Gravis
- 2016 Top Stories in Neurology: Zika Virus and Guillain–Barré Syndrome
- 2015 Top Stories in Neurology: CIDP Unresponsive to Therapy